• <menu id="eaywc"><menu id="eaywc"></menu></menu>
  • Building a Leading BioPharma Company

    Chairman and CEO Giovanni Caforio reflects on the combination of Bristol-Myers Squibb and Celgene

    November 20, 2019 | Giovanni Caforio, Chairman and Chief Executive Officer, Bristol-Myers Squibb

    T

    oday,?Bristol-Myers Squibb and Celgene?officially?come together to?build?a?leading biopharma company?focused on?transforming?the?lives of patients through science.

    Giovanni Caforio Becomes PhRMA Chair

    Giovanni Caforio, Chairman and Chief Executive Officer, Bristol-Myers Squibb

    We are united in our mission to discover, develop and deliver innovative medicines to help patients prevail over serious diseases — and we’re pioneering new treatments that give people back their lives.?It is a momentous day?that marks the beginning of a new chapter of opportunity and promise?as we?harness?our collective groundbreaking science,?global scale and agility,?industry-leading commercialization capabilities?and the?passion and expertise?of?our people.

    Achieving this milestone?is a testament to the tireless work of our employees, the support of our partners and the belief of our shareholders in the value of?our combined company.?

    We are united in our singular focus on patients. They are at the center of everything we do.
    Giovanni Caforio Becomes PhRMA Chair

    Our expanded R&D organization is poised to search for the next opportunity to reinvent medicine and how it’s delivered.

    Our vision for the future is to work together to lead scientific innovation in the charge against cancer and other serious diseases with a goal to solve unmet medical needs. With an expanded, best-in-class R&D organization and a high-performing commercialization team, we are poised to leverage our global scale and agility to search for the next opportunity to reinvent medicine and how it’s delivered. We now have leading franchises in oncology, hematology, cardiovascular disease and immunology, as well as one of the most diverse and promising pipelines in the industry. Most importantly, we have highly talented and deeply passionate people to drive us forward.???

    We are united in our singular focus on patients.?They?are at the center of everything we do.?Our patients?inspire us to do more, reach further?and?work harder?because we know they are waiting for the next innovative?medicine.

    I?am confident?that?we?will?deliver?more medicines to more?patients?and create value for our?employees and shareholders?as we?strengthen?our scientific leadership and evolve to a broad portfolio of marketed assets.?I?am excited about?what we?will accomplish?together.?

    Related Content

    Achieving Our Vision Through Leading Scientific Innovation

    Achieving Our Vision Through Leading Scientific Innovation

    The new company is united by one vision for the future, and we are already making tangible progress toward achieving it.

    青青草偷拍国产视频